SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
|☐||Preliminary Proxy Statement|
|☐||Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))|
|☐||Definitive Proxy Statement|
|☒||Definitive Additional Materials|
|☐||Soliciting Material under § 240.14a-12|
Athira Pharma, Inc.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
No fee required
Fee paid previously with preliminary materials
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote FOR All of Athiras Highly Qualified Director Nominees
Joins Institutional Shareholder Services in Recommending a Vote on Athiras WHITE Proxy Card
Athira Urges Shareholders to Vote FOR Athiras Highly Qualified, Independent Director Nominees Joseph Edelman, John M. Fluke, Jr. and Grant Pickering on the WHITE Proxy Card Today
BOTHELL, WA, May 5, 2022 Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that leading independent proxy advisory firm Glass, Lewis & Co., LLC (Glass Lewis) has recommended that shareholders vote FOR all three of Athiras director nominees Joseph Edelman, John M. Fluke, Jr. and Grant Pickering on the WHITE proxy card.
In making its recommendations, Glass Lewis stated in its May 5, 2022, report1:
Again, where Mr. Kaynes platform notionally asserts critical change is needed in this case, with respect to sector expertise it appears achievement of that change is ultimately subordinate to Mr. Kayne obtaining a board seat.
analyses disclosed by both Athira and Mr. Kayne suggest the Company has outperformed noted benchmarks since [Mark Littons] appointment [as CEO].
As such, we do not consider [Mr. Kaynes and Mr. Bickerstaffs] appointments necessarily portend significant, favorable change in this regard, and would, instead, express concern that their elections could be problematically destabilizing at a critical juncture for Athira despite what appear to be good faith efforts by the board to resolve the current contest.
Much to the contrary, we are concerned the current campaign is disconcertingly titled (sic) toward offering overly favorable representations of Mr. Kaynes current business associate and the Companys former CEO, while providing investors with a very limited plan and a potentially compromised slate.
In this case, having reviewed available arguments, we do not believe the Dissident has provided investors with suitable cause to conclude additional change to the Athira board is necessary at this time.
Accordingly, we recommend shareholders use managements WHITE proxy card to vote FOR all nominees.
Permission to use quotations neither sought nor obtained.
Commenting on the Glass Lewiss recommendation, the Athira Board of Directors issued the following statement:
We are pleased that Glass Lewis recognizes the talent of our three highly qualified board nominees and the work that our board has done to oversee execution and keep Athira on the right track to deliver value for our shareholders, especially as we enter a critical time for the company.
Athiras board and leadership team are focused on doing what is right for Athira, our shareholders and our patients and their caregivers. We have the right strategy, as well as the right leadership team and board of directors, to drive Athiras success in this pivotal chapter. With topline results from the Phase 2 ACT-AD study expected by the end of the second quarter of 2022 and other key clinical event catalysts on the horizon, it is important that our progress not be disrupted.
We are grateful Glass Lewis joined ISS in recognizing the self-serving nature of Richard A. Kaynes campaign, which is centered on installing Mr. Kayne as a director, and recommending that Athira shareholders vote on the WHITE proxy card.
We urge shareholders to follow Glass Lewiss recommendation and vote FOR our highly qualified directors Joseph Edelman, John M. Fluke, Jr. and Grant Pickering on the WHITE proxy card today.
Athira reminds shareholders that every vote is important. Shareholders are urged to discard any blue proxy materials and only to vote using the WHITE proxy card.
Goldman Sachs & Co. LLC is serving as financial advisor to Athira. Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal advisor to Athira.
About Athira Pharma, Inc.
Athira Pharma Inc., headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its pipeline therapeutic candidates, targeting the HGF/MET neurotrophic system, for Alzheimers and Parkinsons disease dementia, Dementia with Lewy bodies and neuropsychiatric indications. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding fosgonimeton as a potential treatment for Alzheimers disease, Parkinsons disease dementia, Dementia with Lewy bodies, and other dementias; Athiras platform technology and potential therapies; future development plans; clinical and regulatory objectives and the timing thereof, including the timing of the ACT-AD and LIFT-AD clinical trials and the timing of the Phase 2 clinical trial of fosgonimeton for treatment of Parkinsons disease dementia; interactions with regulators and the timing thereof, including anticipated timing of IND or equivalent submissions; expectations regarding the potential efficacy and commercial potential of Athiras product candidates; the anticipated reporting of data; and Athiras ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, on track, would, expect, plan, believe, intend, pursue, continue, and other similar expressions, among others. Any forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the proxy contest at Athiras annual meeting; preliminary data for Athiras fosgonimeton product candidate from the Phase 1a/b trials will not continue or persist in current or planned clinical trials; cessation or delay of any of the ongoing clinical trials and/or Athiras development of fosgonimeton and other product candidates may occur; future potential regulatory milestones of fosgonimeton and other product candidates, including those related to current and planned clinical studies may be insufficient to support regulatory submissions or approval; the impact of the COVID-19 pandemic on Athiras business, research and clinical development plans and timelines and results of operations, including impact on Athiras clinical trial sites and contractors who act for or on Athiras behalf, may be more severe and more prolonged than currently anticipated; the regulatory process for Athira product candidates; the outcome of legal proceedings that have been or may in the future be instituted against us and certain of our directors and officers; clinical trials may not demonstrate safety and efficacy of any of Athiras product candidates; Athiras assumptions regarding the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; Athiras research and development efforts and its ability to advance product candidates into later stages of development may fail; any one or more of Athiras product candidates may not be successfully developed, approved or commercialized; adverse conditions in the general domestic and global economic markets; the impact of competition; while P300 latency is a functional measure that is highly correlated with cognition, Athira may not successfully establish a connection between these P300 latency results and improved cognition; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athiras clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athiras filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.
Investor & Media Contacts:
Andy Brimmer / Jamie Moser / Melissa Johnson
Joele Frank, Wilkinson Brimmer Katcher